Clinical trial
Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
NCT00198380 · Intergroupe Francophone de Cancerologie Thoracique, Other · Completed
Key facts
| NCT number | NCT00198380 |
|---|---|
| Title | Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature |
| Official title | Phase II of Gefitinib (IRESSA) Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma (P-ADC) |
| Lead sponsor | Intergroupe Francophone de Cancerologie Thoracique, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pneumonic-type Adenocarcinoma (P-ADC), Lung Adenocarcinoma With Bronchiolo-alveolar Feature |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 90 |
| Start date | Apr 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 8, 2024 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: